Access brought to you by: LOCKSS

Oncology Clinical Trials

Breast Cancer: Updated Overall Survival Results from EMILIA
Phase 3 Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK-Positive NSCLC
CORRECT Trial of Regorafenib in Metastatic Colorectal Cancer: Overall Survival Update
A Paradigm Shift in Early Drug Development: Individualizing to More Patient Benefit
AURELIA Analysis Shows Benefits of Bevacizumab as Add-on Therapy in Ovarian Cancer
Results and Subgroup Analyses of the PETACC-8 Trial
Single-Agent Doxorubicin versus Doxorubicin Plus Ifosfamide in Advanced Soft Tissue Sarcoma
Docetaxel is Widely Used in Treatment of Breast Cancer in China
Results of the EXTREME Study
Consolidation with Arsenic Trioxide Significantly Improves Event-free Survival and Overall Survival among Patients with Newly Diagnosed Acute Promyelocytic Leukemia

Pages